Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Lopez

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Acta Obstetricia Et Gynecologica Scandinavica|August 22, 2024
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trialMarta Ricart, Erika Bonacina, Pablo Garcia-Manau, et al.
Journal of Hepatology|August 24, 2018
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trialElsa Solà, Cristina Solé, Macarena Simón-Talero, et al.
JAMA|February 22, 2023
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical TrialManel Mendoza, Erika Bonacina, Pablo Garcia-Manau, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 9, 2023
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trialErika Bonacina, Pablo Garcia-Manau, Monica López, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|September 29, 2025
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised TrialErika Bonacina, Mireia Armengol-Alsina, Pablo Garcia-Manau, et al.
JMIR Research Protocols|October 12, 2022
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled TrialPablo Garcia-Manau, Manel Mendoza, Erika Bonacina, et al.
Nature Medicine|January 8, 2025
Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trialPablo Garcia-Manau, Erika Bonacina, Raquel Martin-Alonso, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Acta Obstetricia Et Gynecologica Scandinavica|August 22, 2024
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trialMarta Ricart, Erika Bonacina, Pablo Garcia-Manau, et al.
Journal of Hepatology|August 24, 2018
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trialElsa Solà, Cristina Solé, Macarena Simón-Talero, et al.
JAMA|February 22, 2023
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical TrialManel Mendoza, Erika Bonacina, Pablo Garcia-Manau, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 9, 2023
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trialErika Bonacina, Pablo Garcia-Manau, Monica López, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|September 29, 2025
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised TrialErika Bonacina, Mireia Armengol-Alsina, Pablo Garcia-Manau, et al.
JMIR Research Protocols|October 12, 2022
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled TrialPablo Garcia-Manau, Manel Mendoza, Erika Bonacina, et al.
Nature Medicine|January 8, 2025
Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trialPablo Garcia-Manau, Erika Bonacina, Raquel Martin-Alonso, et al.
Pageof 4